

*The Therapeutic Potential of  
Lentivector-delivered RNAi*

*Nicholas Paul Casey, B.Sc. (Hons.),  
M.Sc. (Research)*

*Menzies Research Institute, University of  
Tasmania*

*A thesis submitted in fulfilment of the  
requirements for the degree of Doctor of Philosophy.*

*University of Tasmania*

*November 2010*

## Abstract

Many forms of leukaemia are caused by chromosomal translocations, which result in specific and characteristic genomic sequences. Where these sequences are unique to the leukaemic cells, they represent good candidates for targeting by sequence-specific techniques, such as RNA-Interference (RNAi). RNAi is a mechanism inherent in eukaryotic cells which silences target mRNAs based on homology to a dsRNA template. This template may be introduced artificially by a number of methods, and so this mechanism can be manipulated to regulate the expression of target genes. One of the most efficient methods of introducing RNAi templates is by expression of short-hairpin RNA (shRNA) cassettes from DNA plasmids or vectors.


Lentiviral vectors are based on viruses that integrate into the DNA of the host cell, and are a highly efficient class of vectors for transducing and providing stable transgene expression in a range of cell types. They are particularly effective at transducing haematopoietic cells, which have proven difficult to transduce by other methods. By fine-tuning the methods of vector production and transduction, a range of human leukaemic cell lines were able to be transduced with unprecedented efficiency in the present study. Lentiviral transduction was combined with rapid puromycin selection to generate a pure population of transduced cells with minimal expansion of the cell population.

The strategy of expressing shRNAs from retroviral and lentiviral vectors combined with puromycin selection was used to target three well-characterised fusion genes; Bcr-Abl, PML/RAR $\alpha$  and RUNX1/ETO, in three human leukaemic cell lines. In two of these, the shRNA was able to efficiently and effectively down-regulate the target mRNA, and inhibit the proliferation of the transduced leukaemic cells. In the third case, RUNX1/ETO, no effective shRNA design could be identified.

Finally, concerns over the safety of integration targeting by current gene therapy vectors motivated an investigation of the activity of a novel integrase enzyme from the Ty3 retrotransposon found in yeast. In yeast cells, the integration-mediating enzyme of this retrotransposon has very specific targeting characteristics, which, if retained in human cells, would provide a very safe gene therapy vector. It was found that this enzyme is indeed active in human cells, and therefore has potential in the context of human gene therapy.

## **Declaration**


I certify that this thesis contains no material which has been accepted for a degree or diploma by the University or any other institution, and that to the best of my knowledge and belief, no material previously published or written by another person has been utilised in the preparation of this thesis, except where due acknowledgement is made in the text, nor does this thesis contain any material which infringes copyright.

A handwritten signature in black ink, appearing to read 'N. Casey', is centered on the page. The signature is written in a cursive style with a long horizontal stroke at the end.

Nicholas Paul Casey

## Copyright statement

This thesis may be made available for loan and limited copying in accordance with the *Copyright Act 1968*.

A handwritten signature in dark ink, appearing to read 'N. Casey', is centered on a light blue rectangular background.

Nicholas Paul Casey

## **Publications**

Part of the work contained in this thesis has been published or submitted for publication as detailed below:

Brozik, A., N.P. Casey, C. Hegedus, A. Bors, A. Kozma, H. Andrikovics, M. Geiszt, K. Nemet and M. Magocsi (2006). "Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK." Annals of the New York Academy of Sciences **1090**: 344-54.

## **Statement of Ethical Conduct**

The research associated with this thesis abides by the international and Australian codes on human and animal experimentation, the guidelines of the Australian Government's Office of the Gene Technology Regulator and the rulings of the Safety, Ethics and Institutional Biosafety Committees of the University.

## List of Abbreviations

6-FAM	6-CarboxyFluorescein-Aminoethyl Amidite
AAV	Adeno-Associated Virus
Abl	Abelson Leukemia
AE(1/2/3)	AML1-ETO shRNA design (1/2/3)
AIDS	Acquired Immuno Deficiency Syndrome
ALL	Acute Lymphoblastic Leukaemia
AML	Acute myeloid Leukaemia
AML1	Acute myeloid Leukaemia-1
AP-1	Activator Protein 1
APL	Acute Promyelocytic Leukemia
ASLV	Avian Sarcoma Leukosis Virus
ASV	Avian Sarcoma Virus
ATCC	American Type Culture Collection
ATO	Arsenic Tetroxide
ATP	Adenosine Triphosphate
ATRA	All Trans-Retinoic Acid
B2M	Beta-2-microglobulin
Bcr	Breakpoint cluster region
BLAST	Basic Local Alignment Search Tool
bp	base pairs
CAG	Cytomegalovirus early enhancer element and chicken beta-actin promoter
CBFA2	Core-Binding Factor, runt domain, Alpha subunit 2
CBP	CREB (cAMP response element-binding)-Binding Protein
CD(nn)	Cluster Differentiation marker number (nn)
CML	Chronic Myelogenous Leukemia
CMV	Cytomegalovirus
CpG	C-phosphate-G
DAI	dsRNA-Activated Inhibitor
DMEM	Dulbecco's Modified Eagle Medium

DMSO	Dimethyl Sulfoxide
DNA	Deoxyribonucleic Acid
ECL	Enhanced Chemiluminescence
EDTA	Ethylenediaminetetraacetic Acid
EF1 $\alpha$	Elongation Factor 1 $\alpha$
EGFP	Enhanced Green Fluorescent Protein
EGTA	Ethylene Glycol Tetraacetic Acid
EIAV	Equine Infectious Anemia Virus
ERK	Extracellular-signal-Regulated Kinases
ETO	Eight Twenty-One
FAB	French-American-British
FACS	Fluorescence-Activated Cell Sorting
FCS	Foetal Calf Serum
FISH	Fluorescent In Situ Hybridization
FIV	Feline Immunodeficiency Virus
GAPDH	Glyceraldehyde 3-Phosphate Dehydrogenase
G-CSF	Granulocyte Colony-Stimulating Factor
gDNA	Genomic Deoxyribonucleic Acid
GFP	Green Fluorescent Protein
GRB2	Growth Factor Receptor-Bound protein 2
HAT	Histone Acetyl Transferase
HBS	Hepes Buffered Saline
HDAC	Histone Deacetylase
HEK	Human Embryonic Kidney
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HERV	Human Endogenous Retrovirus
HI-FCS	Heat Inactivated Foetal Calf Serum
HIV	Human Immunodeficiency Virus
HSV	Herpes Simplex Virus
IFN	Interferon
IL2	Interleukin-2
IL2RG	Interleukin-2 Receptor subunit gamma



IN	Integrase
IRES	Internal Ribosomal Entry Site
ISG	Interferon-Stimulated Gene
JAK	Janus Kinase
kb	kilo-bases
kDa	kilo-Daltons
K-RAS	Kirsten Rat Sarcoma viral oncogene homolog,
LAM-PCR	Linear Amplification Mediate-Polymerase Chain Reaction
LMO2	LIM domain Only 2
LTR	Long Terminal Repeats
Lys	Lysine
MAPK	MAP (Mitogen-Activated Protein) Kinase
MEK	MAPK/ERK Kinase
MFI	Mean Fluorescence Intensity
miRNA	micro-Ribonucleic Acid
MLV	Murine Leukemia Virus
MoMLV	Moloney Murine Leukemia Virus
mRNA	messenger Ribonucleic Acid
MTG8	Myeloid Translocation Gene 8
N-CoR	Nuclear receptor Co-Repressor 1
nef	negative regulatory factor
NHR	Nuclear Hormone Receptor
NS	Nonsense shRNA design
OAS	Oligoadenylate Synthetase
ORF	Open Reading Frame
PAGE	Poly-Acrylamide Gel Electrophoresis
PBS	Phosphate Buffered Saline
PCR	Polymerase Chain Reaction
PEBP2 $\alpha$ B	Polyomavirus Enhancer Binding Protein 2 alpha B
(p)ERK	(phosphorylated) Extracellular signal-Regulated Kinase
PIWI	P-element Induced Wimpy testis
PKR	Protein Kinase R

PLZF	Promyelocytic Leukemia Zinc Finger
PML	Promyelocytic Leukemia
PNPP	p-Nitrophenyl Phosphate
POD	PML Oncogenic Domain
PolIII	Polymerase class III
PR(1/2)	PML/RAR $\alpha$ shRNA design (1/2)
PUROR	Puromycin resistance gene
PVDF	Polyvinylidene Fluoride
qRT-PCR	Quantitative Reverse Transcript Polymerase Chain Reaction
RA	Retinoic Acid
RAR $\alpha$	Retinoic Acid Receptor alpha
RARE	Retinoic Acid Responsive Element
RAS	Rat Sarcoma
RING	Really Interesting New Gene
RISC	RNA-Induced Silencing Complex
RNase	Ribonuclease
RPMI	Roswell Park Memorial Institute
RUNX1	Runt-related transcription factor 1
SDS	Sodium Dodecyl Sulfate
shRNA	short-hairpin Ribonucleic Acid
siRNA	short-interfering Ribonucleic Acid
SMRT	Silencing Mediator for Retinoid and Thyroid-hormone receptors
SNFW	Sterile Nuclease-Free Water
SRC	Sarcoma
SSC	Saline Sodium Citrate
STAT(1/5)	Signal Transducers and Activators of Transcription
SUP2	Suppressor 2
SYBR	Synergy Brands
TBS	Tris Buffered Saline
TFIII	Transcription Factor III
TIF1 $\alpha$	Transcriptional Intermediary Factor 1 alpha
tRNA	transfer RNA

vif	viral infectivity factor
vpr	viral protein R
VSV-G	Vesicular Stomatitis Virus G
WPRE	Woodchuck hepatitis post-transcriptional regulatory element
X-SCID	X-linked Severe Combined Immunodeficiency

## Table of Contents

The Therapeutic Potential of Lentivector-delivered RNAi.....	i
Abstract .....	ii
Declaration .....	iii
Copyright statement .....	iv
Publications .....	v
List of Abbreviations .....	vi
Statement of Ethical Conduct .....	vi
Table of Contents .....	xii
List of Figures .....	xx
1 Literature Review .....	1
1.1 Outline.....	1
1.2 Leukaemia.....	2
1.2.1 Chronic Myelogenous Leukaemia (CML).....	3
1.2.1.1 Bcr/Abl Breakpoint .....	4
1.2.1.2 Neutralisation of the Bcr/Abl Fusion Gene.....	6
1.2.2 Acute Promyelocytic Leukaemia (APL).....	7
1.2.2.1 PML-RAR $\alpha$ Breakpoint .....	9
1.2.2.2 Neutralisation of the PML-RAR $\alpha$ Fusion Gene.....	10
1.2.3 Acute Myeloid Leukaemia (AML) – RUNX1/ETO .....	11
1.2.3.1 RUNX1-ETO Breakpoint .....	13
1.2.3.2 Neutralisation of the RUNX1-ETO Fusion Gene .....	13
1.3 RNA Interference .....	14
1.3.1 RNAi and Antisense RNA .....	16
1.3.2 Non-Specific Activities of siRNAs.....	16
1.3.2.1 miRNA-like Activity.....	17
1.3.2.2 Interferon Response .....	17
1.3.2.3 Overload Toxicity .....	18
1.4 Expression of shRNAs .....	18
1.5 RNA Interference Targeting Oncogenes.....	19
1.5.1 Delivery of siRNA .....	19

1.5.2	Vector Delivery of shRNA .....	19
1.5.3	Stable Transduction of shRNA as a Therapy for Leukaemia .....	20
1.6	Gene Therapy .....	21
1.6.1	Vector Delivery of therapeutic transgenes .....	21
1.6.1.1	Adeno-associated viruses .....	21
1.6.1.2	Herpes Simplex Virus .....	22
1.6.1.3	Retroviruses .....	22
1.6.1.4	Lentiviral Vectors and Transduction of Non-mitotic Cells .....	23
1.6.2	Enhancing the Safety of Retroviral and Lentiviral Vectors .....	23
1.6.2.1	Self-Inactivating Retrovectors .....	24
1.6.2.2	Fragmentation of the Retrovirus Genome and Use of Packaging Cells .....	24
1.6.3	Markers for Elimination of Non-transduced Cells .....	25
1.6.4	A Comparison of Retrovectors and Lentivectors .....	26
1.6.5	Transduction of Haematopoietic Stem Cells .....	26
1.6.6	Retroviral Integrases and Targeting of Integration .....	27
1.6.6.1	Targeting Preferences of Currently-Used Vectors .....	28
1.6.6.2	Integration Targeting Characteristics of Other Retroviral Groups .....	29
1.6.7	Safety Concerns and Insertional Mutagenesis .....	30
1.6.8	Selection Pressures on Other Integrating Elements .....	31
1.6.9	Retrotransposons .....	31
1.6.10	Ty3 Integrase and Human Genes .....	33
1.7	Aims .....	33
2	General Materials and Methods .....	35
2.1	Cell Culture .....	35
2.2	Cloning .....	35
2.3	Culture and Transformation of Bacteria .....	36
2.3.1	Transformation, Culture and Screening of Bacteria .....	36
2.3.2	Glycerol Stocks .....	37
2.4	Hairpin Design, Annealing and Nonsense Control .....	37
2.5	Vector Construction .....	38

2.6	Production of Infectious Vector Particles .....	39
2.7	Transduction of target cells with purified vector .....	39
2.8	Quantitative Reverse Transcription Polymerase Chain Reactions (qRT-PCRs) .....	40
2.8.1	RNA Isolation .....	40
2.8.2	qRT-PCR Chemistry .....	41
2.8.3	'House-keeping' Genes .....	41
2.8.4	Standard Curves .....	42
2.8.5	Analysis of Rotorgene Results .....	42
2.9	Western Blotting .....	43
2.9.1	Isolation of Nuclear and Cytosol Extracts .....	43
2.9.2	Polyacrylamide Gel Electrophoresis (PAGE).....	44
2.9.3	Electro-Blotting.....	44
2.9.4	Antibody Staining .....	44
2.9.5	Enhanced Chemi-Luminescent Detection.....	45
2.9.6	Semi-Quantitative Analysis of Western Blots .....	45
2.9.7	Cell Proliferation and Viability Assays .....	45
2.9.8	Statistical Analyses .....	46
2.10	List of Buffers, Media .....	46
2.11	List of Reagents and Suppliers.....	50
3	Vector Adaptation.....	52
3.1	Introduction .....	52
3.2	Materials and Methods.....	54
3.2.1	Transfection of Packaging Cells .....	54
3.2.1.1	293T Packaging Cells .....	54
3.2.1.2	Culture Vessels .....	54
3.2.1.3	Comparison of Three-plasmid and Four-plasmid Packaging Systems .....	55
3.2.1.4	Concentration of Vector .....	55
3.2.1.5	Storage and Reconstitution of Vector Pellet .....	56
3.2.2	Methods for Transduction of Refractory Cell Types .....	56
3.2.3	Transduction of Kasumi Cells.....	57

3.2.4	Orientation of shRNA cassette.....	57
3.2.5	Vector Backbones Incorporating Antibiotic Resistance .....	58
3.2.5.1	PUROr into pHIV-7-GFP .....	58
3.2.5.2	Bicistronic Vectors.....	58
3.2.5.2.1	psh-PIG-LV .....	60
3.2.5.2.2	pPIG-2sh-LV .....	60
3.2.5.2.2.1	LoxP Reactions .....	61
3.2.5.2.2.2	pPIG-MUT-LV .....	61
3.2.6	Puromycin Kill Curves.....	63
3.2.7	Activity of PUROr in the Alternate Lentiviral Backbones .....	63
3.3	Results .....	64
3.3.1	Transfection of Packaging Cells .....	64
3.3.1.1	Effect of Culture Vessels on Transfection Rates .....	64
3.3.1.2	Second vs Third Generation Packaging Systems.....	64
3.3.2	Tubes for Ultracentrifugation.....	65
3.3.3	Transduction of Target Cells.....	65
3.3.3.1	Resuspension and Storage of Vector Supernatant .....	65
3.3.3.2	Spinoculation and Repeated Transductions .....	66
3.3.3.3	Transduction of Kasumi Cells.....	67
3.3.4	Orientation of shRNA cassette.....	68
3.3.5	Puromycin Kill curves .....	68
3.3.6	Activity of PUROr Marker Gene in pHIV-PUROr-GFP .....	69
3.3.7	PUROr Activity in the Bicistronic Constructs .....	69
3.3.7.1	Dose and Effect of Puromycin .....	70
3.3.7.2	Activity of PUROr in Alternate Vector Constructs .....	70
3.4	Discussion .....	72
3.4.1	Summary .....	76
4	Down-regulation of Bcr-Abl by RNAi leads to erythroid differentiation ..	78
4.1	Introduction .....	78
4.2	Methods.....	80
4.2.1	Retrovirus-vector construction.....	80
4.2.2	Virus Production .....	80

4.2.3	Preparation of cell extracts.....	81
4.2.4	Western Blotting .....	81
4.2.5	Preparation of total RNA and quantitative measurement of β-globin mRNA levels by the LightCycler System .....	81
4.2.6	Puromycin Selection .....	82
4.2.7	Flow-cytometric Analysis .....	82
4.2.8	Fluorescent <i>In Situ</i> Hybridisation .....	82
4.2.9	Statistical Analyses .....	83
4.3	Results .....	84
4.3.1	Fluorescent In Situ Hybridisation .....	84
4.3.2	Transduction efficiency of the retroviral vector.....	84
4.3.3	Puromycin Treatment of Transduced Cells .....	85
4.3.4	MEK-ERK Signalling Pathway .....	85
4.3.5	Differentiation Markers.....	86
4.4	Discussion .....	87
4.4.1	Conclusion .....	90
5	Down-regulation of PML-RARα by RNAi .....	91
5.1	Introduction .....	91
5.2	Methods.....	93
5.2.1	Transduction of NB4 cells with lentiviral vectors .....	93
5.2.2	Hairpin Design .....	93
5.2.2.1	PR1 and PR2 Hairpin Designs .....	93
5.2.2.2	Control shRNAs .....	94
5.2.3	qRT-PCR Assays .....	94
5.2.3.1	SYBR Green Primers .....	95
5.2.3.2	Plexor Primers.....	95
5.2.4	Puromycin Treatment.....	95
5.2.5	Retinoic Acid treatment .....	95
5.2.6	Cell Cycle Analysis.....	95
5.2.7	Differentiation Assays.....	96
5.3	Results .....	97
5.3.1	Selection of anti-PML-RARα and control shRNAs.....	97



5.3.1.1	PR1 vs PR2 .....	97
5.3.1.2	Testing of ‘inverted centre’ control hairpin .....	97
5.3.1.3	Testing for non-specific effects.....	98
5.3.2	Activity of PR2 Hairpin in Down-regulating the PML-RAR $\alpha$ Fusion mRNA and Protein .....	98
5.3.2.1	qRT-PCR results .....	98
5.3.2.2	Western Blots .....	99
5.3.2.3	Cell Proliferation and Apoptosis.....	99
5.3.2.4	Cell Cycling .....	100
5.3.3	Proliferation of Purified PR2 Transduced Cells .....	101
5.3.3.1	Activity of shRNA in the pPIG-2sh-LV vector .....	101
5.3.3.2	Sensitisation to Stress of ‘Spinoculation’ .....	102
5.3.3.3	Effect of Addition of Fresh Medium.....	102
5.3.3.4	Threshold effect .....	103
5.3.3.5	Summary .....	103
5.3.4	Sensitivity to Retinoic Acid .....	104
5.3.5	Conclusions .....	105
5.4	Discussion .....	106
5.4.1	Summary .....	111
6	Down-regulation of RUNX1-ETO by RNAi.....	112
6.1	Introduction .....	112
6.2	Methods.....	114
6.2.1	Kasumi Cell Culture and Transduction.....	114
6.2.2	Hairpin Design .....	114
6.2.3	Observations of Cell Shape and Appearance .....	115
6.2.4	qRT-PCR.....	116
6.2.5	Cell Proliferation Assays .....	116
6.3	Results .....	117
6.3.1	Delayed Transgene Expression .....	117
6.3.2	qRT-PCR.....	117
6.3.2.1	AE1 Hairpin .....	117
6.3.2.2	AE2 Hairpin .....	118

6.3.2.3	AE3 Hairpin .....	119
6.3.2.4	Summary of qRT-PCR Results .....	120
6.3.3	Cell Proliferation assays.....	120
6.3.4	Appearance of Cells .....	121
6.4	Discussion .....	122
6.4.1	Conclusion .....	124
7	Activity of Ty3 Integrase in Human Cells.....	125
7.1	Introduction .....	125
7.1.1	Methods.....	128
7.1.1.1	Expression Vectors .....	128
7.1.2	Marker ‘Integrand’ .....	130
7.1.3	Puromycin Selection .....	131
7.1.4	Co-transfection.....	131
7.1.5	Monitoring for Marker Gene Expression.....	132
7.1.6	Screening gDNA for integration of expression vectors .....	133
7.1.7	Identification of Integration targeting sites .....	133
7.1.7.1	Restriction Enzyme .....	133
7.1.7.2	Forward Primer Design .....	134
7.1.7.3	Sequencing .....	134
7.1.8	Screening of gDNA for Integrated Copies of the Marker Gene .	135
7.2	Results .....	136
7.2.1	Long-term Expression of Marker Transgene in Human Cell Colonies .....	136
7.2.2	Screening for PUOR Marker Gene of the Expression Vectors .	137
7.2.3	Gel-Separation of LAM-PCR Products .....	137
7.2.4	LAM-PCR Sequencing Results .....	137
7.2.5	Screening gDNA for GFP Transgene .....	139
7.3	Discussion .....	140
7.3.1	Conclusions .....	144
8	General Discussion .....	145
8.1	Future Investigations.....	152
8.2	Conclusions .....	153

9	Bibliography .....	155
	Appendices .....	186

## List of Figures

Figure 1.1 Domains of the Bcr, Abl, and Bcr-Abl proteins

Figure 1.2 Domains of the PML and RAR $\alpha$  proteins

Figure 1.3 Domains of the RUNX1/ETO protein

Figure 1.4 The RNA Interference Pathway.

Figure 1.5 Retroviral Life Cycle

Figure 2.1 pHIV-7-GFP-NSf

Figure 2.1 pHIV-7-GFP-NSf

Figure 3.1 pHIV-7-GFP-NSr

Figure 3.2 pPIG-2sh-LV Vector

Figure 3.3 Activity of shRNA Cassettes in the Forward and Reverse  
Orientations

Figure 3.4 The Effect of Puromycin on the Number of Viable Cells Transduced  
with Biscistronic Vectors

Figure 4.2 FISH Probing for Bcr/Abl Chromosomal Translocations

Figure 4.3 Flow Cytometry of Transduced Cells

Figure 4.4 Flow Cytometry of Transduced Cells Following Puromycin Selection

Figure 4.5 Western Blots

Figure 4.6 Normalised Levels of Bcr/Abl Protein

Figure 4.7 Normalised Levels of Phosphorylated ERK Protein

Figure 4.8 Levels of  $\beta$ -Globin mRNA at Day 6 Post-Transduction

Figure 4.9 Normalised Levels of PU.1 Protein

Figure 5.1 NS vs PR1 vs PR2 shRNAs

Figure 5.2 Relative activity of NS, PR2 and the novel PRK control

Figure 5.3 OAS levels at 48 hours after transduction

Figure 5.4 PML-RAR $\alpha$  mRNA levels following treatment with shRNAs

Figure 5.5 Average down-regulation of PML-RAR $\alpha$  mRNA relative to controls

Figure 5.6A Western blot of RAR $\alpha$  and PML-RAR $\alpha$  proteins

Figure 5.6B  $\beta$ -actin loading control

Figure 5.7 Relative Band Intensity

Figure 5.8 Proliferation of transduced cells

Figure 5.9 Cell death following transduction

Figure 5.10 Cell Cycling

Figure 5.11 Levels of PML-RAR $\alpha$  mRNA in purified cells

Figure 5.12 Relative proliferation of purified cells

Figure 5.13 Proliferation of cells without spinoculation

Figure 5.14 Effect of replenishing culture media

Figure 5.15 Fluorescence of purified transduced cells

Figure 5.16 Effect of ATRA on NB4 cell proliferation

Figure 5.17 Sensitivity of PR2 transduced cells to ATRA treatment

Figure 5.18 Proliferation of purified transduced NB4 cells after 72 hours ATRA treatment

Figure 5.19 Labelling of sorted transduced NB4 cells for myeloid differentiation markers after 72 hours ATRA treatment

Figure 5.20 Labelling of transduced, puromycin selected NB4 cells for myeloid differentiation markers after 72 hours ATRA treatment

Figure 6.1 RUNX1-ETO mRNA Levels from AE1 treated Kasumi cells

Figure 6.2 RUNX1-ETO mRNA Levels from AE2 treated Kasumi cells

Figure 6.3 RUNX1-ETO mRNA Levels from AE3 treated Kasumi cells

Figure 6.4 Relative cell growth of Kasumi cells treated with AE1, AE2 or AE3 shRNAs

Figure 6.5 Relative cell growth of Kasumi cells treated with AE1 or AE2 shRNAs

Figure 7.1 - pLV-3IN-IRES-PURO

Figure 7.2 Overview of the Marker Integrant

Figure 7.3 Relative numbers of fluorescent and mosaic colonies following treatment with Ty3 integrase

Figure 7.4 Probing for integrated expression vectors

Figure 7.5 LAM-PCR products from integrase treated colonies

Figure 7.6 LAM-PCR Products from of control treated, fluorescent colonies

Figure 7.7 Probing gDNA for Integrated Marker Sequence